Citations

Clear

1053 citation(s) found for "Andre, F".

BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database
Cohen, Romain , Liu, Heshan , Fiskum, Jack, Adams, Richard , Chibaudel, Benoist , Maughan, Tim , Venook, Alan P. , Douillard, Jean‐Yves , Heinemann, Volker , Punt, Cornelis J.A. , Bokemeyer, Carsten , Lenz, Heinz‐Josef , Koopman, Miriam , Zalcberg, John , Grothey, A., Gramont, Aimery de , Shi, Qian , Maughan, Timothy S , Venook, Alan P , Heinemann, Volker , Falcone, Alfredo , Bokemeyer, Carsten , Kaplan, Richard , Lenz, Heinz-Josef , Koopman, Miriam , Shi, Qian , Zalcberg, John , Adams, Richard , Chibaudel, Benoist , Cohen, Romain , Cutsem, Eric Van , Falcone, Alfredo , Kaplan, Richard , Yoshino, Takayuki , André, Thierry

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 15, 2021 | Volume: 113 | Issue: 10 | Pages: 1386-1395

10.1093/jnci/djab042 | PMID 33734401 Get It

Abstract Background First-line therapeutic strategies for patients with BRAFV600E-mutated (BRAFmt) metastatic colorectal cancer (mCRC) mainly rely on subgroup analyses from randomized controlled trials (RCTs). We aimed to assess the prognostic and predictive impact of BRAFmt on the efficacy of targeted therapies with first-line chemotherapy. Methods Individual patient data from first-line RCTs with BRAF and KRAS status data in the ARCAD database were pooled. Progression-free survival and overall survival (OS) were assessed using Kaplan-Meier and Cox models. Outcomes were compared between treatment groups that were concurrently randomly assigned whenever possible. Results A total of 6391 patients from 10 RCTs were included: 573 BRAFmt (9.0%), 2059 KRASmt (32.2%), and 3759 double wild type (58.8%). BRAFmt mCRC patients experienced statistically significantly poorer OS than those with KRASmt (adjusted hazard ratio [HRadj] = 1.46, 95% confidence interval [CI] = 1.30 to 1.64) and patients with double wild-type tumors (HRadj = 2.14, 95% CI = 1.94 to 2.36). Anti-EGFR agents did not improve progression-free survival or OS of BRAFmt mCRC patients, based on 4 RCTs testing chemotherapy with or without anti-epidermal growth factor receptor (anti-EGFR) (HRadj = 0.96, 95% CI = 0.71 to 1.30; and HRadj = 0.85, 95% CI = 0.66 to 1.14, respectively). Conclusions Our data suggest that the addition of anti-EGFR agents to chemotherapy is ineffective as first-line treatment for BRAFmt mCRC patients.
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials
Toi, Masakazu , Masuda, Norikazu , Sohn, Joohyuk , Chen, Shin‐Cheh , Enatsu, Sotaro, Turner, P. Kellie , Hardebeck, Molly Catherine , Sakaguchi, Sachi , Masuda, Norikazu , Hae Park, In , Sohn, Joohyuk , Inoue, Kenichi , Iwata, Hiroji , Park, In Hae , Im, Seock‐Ah , André, Valérie , Goetz, Matthew P. , Sledge, George W.

Mayo Clinic

Cancer Science | March 9, 2021 | Volume: 112 | Issue: 6 | Pages: 2381-2392

10.1111/cas.14877 | PMID 33686753 Get It

AbstractThis post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2‐negative (HER2−) advanced breast cancer. MONARCH 2 and MONARCH 3 are global, randomized, double‐blind, phase 3 studies of abemaciclib/placebo + fulvestrant and abemaciclib/placebo + nonsteroidal aromatase inhibitor (NSAI, anastrozole or letrozole), respectively. The East Asian population comprised 212 (31.7%) of the 669 intent‐to‐treat (ITT) population in the MONARCH 2 trial and 144 (29.2%) of the 493 ITT patients in the MONARCH 3 trial. In the East Asian population, median progression‐free survival (PFS) was significantly prolonged in the abemaciclib arm compared with placebo in both MONARCH 2 (hazard ratio [HR], 0.520; 95% confidence interval [CI], 0.362 to 0.747; P < .001; median: 21.2 vs 11.6 months) and MONARCH 3 (HR, 0.326; 95% CI, 0.200 to 0.531, P < .001; median: not reached vs 12.82 months). Diarrhea (MONARCH 2: 90%; MONARCH 3: 88%) and neutropenia (MONARCH 2: 68%; MONARCH 3: 58%) were the most frequent adverse events observed in the East Asian populations. Abemaciclib exposures and PK were similar in East Asians and the non‐East Asian populations of both trials. Abemaciclib in combination with ET in the East Asian populations of MONARCH 2 and MONARCH 3 provided consistent results with the ITT populations, demonstrating improvements in efficacy with generally tolerable safety profiles for patients with HR+, HER2− advanced breast cancer.
Pulmonary Function Changes in the Older adults with and without Metabolic Syndrome
Rangel, Maysa, Moraes-Ferreira, Renilson , Santos‐Dias, Alana, Gabriela-Pereira, Giovana, Freitas, Simone de Oliveira, Araújo-Rosa, Amanda Cristina, Oliveira, Luí­s Henrique Sales , Frison, Claudio Ricardo , Balagopal, Prabhakaran , Vieira, Rodolfo P. , Oliveira‐Junior, Manoel Carneiro , Bachi, André Luís Lacerda , Raju, Raghavan Pillai

Mayo Clinic

No container title available | March 5, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-271946/v1 Get It

Abstract Low-grade inflammation associated with metabolic syndrome (MS) triggers alterations in several organs, but its effects on pulmonary functional and immunological response in older adults are unknown. This cross-sectional study investigated such responses in older adults with and without MS. The study consisted of 77 older adults with MS (68 ± 3 years old) and without MS (67 ± 3 years old). Impulse oscillometry (IOS) was used to evaluate airway and tissue resistance and reactance. Biomarkers of systemic and pulmonary inflammation and fibrosis were studied. Total resistance of respiratory system (R5Hz; p < 0.009), and resistance of proximal (R20Hz; p < 0.001) and distal (R5Hz-R20Hz; p < 0.004) airways were impaired in MS individuals compared to those without MS. The levels of pro-inflammatory (leptin; IL-1beta; IL-8, p < 0.001; TNF-alpha, p < 0.04) and pro-fibrotic (VEGF, p < 0.001) factor increased in MS, while reduced levels of anti-inflammatory cytokines (adiponectin; IL-1ra; IL-10; p < 0.001), and anti-fibrotic (relaxin 1; relaxin 3; Klotho, p < 0.001) factors were found. We conclude that MS accelerates lung function and mechanics impairment in older adults in detriment of an imbalance between pro and anti-inflammatory and fibrotic mediators. Furthermore, this study shows that the lungs also are a target organ in MS, deserving clinical assessment in older adults’ population.
Black phosphorus incorporation modulates nanocomposite hydrogel properties and subsequent MC3T3 cell attachment, proliferation, and differentiation
Xu, Haocheng , Liu, Xifeng , George, Matthew N. , Park, Sungjo , Xu, Hao , Lu, Lichun , Miller, A. Lee , Miller, Alan Lee , Terzic, André

Mayo Clinic

Journal of Biomedical Materials Research Part A | March 2, 2021 | Volume: 109 | Issue: 9 | Pages: 1633-1645

10.1002/jbm.a.37159 | PMID 33650768 Get It

AbstractA promising strategy that emerged in tissue engineering is to incorporate two‐dimensional (2D) materials into polymer scaffolds, producing materials with desirable mechanical properties and surface chemistries, which also display broad biocompatibility. Black phosphorus (BP) is a 2D material that has sparked recent scientific interest due to its unique structure and electrochemical characteristics. In this study, BP nanosheets (BPNSs) were incorporated into a cross‐linkable oligo[poly(ethylene glycol) fumarate] (OPF) hydrogel to produce a new nanocomposite for bone regeneration. BPNSs exhibited a controllable degradation rate coupled with the release of phosphate in vitro. MTS assay results together with live/dead images confirmed that the introduction of BPNSs into OPF hydrogels enhanced MC3T3‐E1 cell proliferation. Moreover, the morphology parameters indicated better attachments of cells in the BPNSs containing group. Immunofluorescence images as well as intercellular ALP and OCN activities showed that adding a certain amount of BPNSs to OPF hydrogel could greatly improve differentiation of pre‐osteoblasts on the hydrogel. Additionally, embedding black phosphorous into a neutral polymer network helped to control its cytotoxicity, with optimal cell growth observed at BP concentrations as high as 500 ppm. These results reinforced that the supplementation of OPF with BPNSs can increase the osteogenic capacity of polymer scaffolds for use in bone tissue engineering.
Regenerative Medicine Clinical Readiness
Yamada, Satsuki , Behfar, Atta , Terzic, André , Behfar, Atta , Terzic, Andre

Mayo Clinic

Regenerative Medicine | February 24, 2021 | Volume: 16 | Issue: 3 | Pages: 309-322

10.2217/rme-2020-0178 | PMID 33622049 Get It

Emerging Workforce Readiness in Regenerative Healthcare
Wyles, Saranya P. , Monie, Dileep D. , Paradise, Christopher R. , Meyer, Fredric B. , Hayden, Richard E. , Terzic, André , van Wijnen, Andre J , Terzic, Andre , Monie, Dileep D

Mayo Clinic

Regenerative Medicine | February 24, 2021 | Volume: 16 | Issue: 3 | Pages: 197-206

10.2217/rme-2020-0137 | PMID 33622054 Get It

Cell Surface Glycoprotein CD24 Marks Bone Marrow-Derived Human Mesenchymal Stem/Stromal Cells with Reduced Proliferative and Differentiation Capacity In Vitro
Peppel, Jeroen van de , Schaaf, Gerben , Matos, Adriana Arruda , Guo, Yuan , Strini, Tanja, Verschoor, W., Dudakovic, Amel , Wijnen, André J. van , Leeuwen, Johannes P.T.M. van , van Wijnen, Andre J

Mayo Clinic

Stem Cells and Development | February 17, 2021 | Volume: 30 | Issue: 6 | Pages: 325-336

10.1089/scd.2021.0027 | PMID 33593128 Get It

Clinical Laboratory Reports in Molecular Pathology
Gulley, Margaret L. , Braziel, Rita M., Halling, Kevin C. , Kant, Jeffrey A., Nowak, Jan A. , Oliveira, André M. , Polesky, Herbert F., Silverman, Lawrence M., Tubbs, Raymond R., Deerlin, Vivianna M. Van, Vance, Gail H. , Versalovic, James , Hsi, Eric D. , Nikiforova, Marina N. , Ogino, Shuji , Deerlin, Vivianna M. Van

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 6 | Pages: 852-863

10.5858/2007-131-852-clrimp | PMID 17550311 Get It

Abstract Context. —Molecular pathology is a rapidly growing area of laboratory medicine in which DNA and RNA are analyzed. The recent introduction of array technology has added another layer of complexity involving massive parallel analysis of multiple genes, transcripts, or proteins. Objective. —As molecular technologies are increasingly implemented in clinical settings, it is important to bring uniformity to the way that test results are reported. Data Sources. —The College of American Pathologists Molecular Pathology Resource Committee members summarize elements that are already common to virtually all molecular pathology reports, as set forth in the College of American Pathologists checklists used in the laboratory accreditation process. Consensus recommendations are proposed to improve report format and content, and areas of controversy are discussed. Resources are cited that promote use of proper gene nomenclature and that describe methods for reporting mutations, translocations, microsatellite instability, and other genetic alterations related to inherited disease, cancer, identity testing, microbiology, and pharmacogenetics. Conclusions. —These resources and recommendations provide a framework for composing patient reports to convey molecular test results and their clinical significance to members of the health care team.
Perineurioma: A Distinctive and Underrecognized Peripheral Nerve Sheath Neoplasm
Ellinger, Fred, Oliveira, André M. , Macarenco, Ricardo

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 4 | Pages: 625-636

10.5858/2007-131-625-padaup | PMID 17425397 Get It

Abstract Context. —Perineuriomas are benign peripheral nerve sheath neoplasms composed of perineurial cells with characteristic immunohistochemical and ultrastructural features. They have been traditionally classified into two main types according to their location—intraneural and extraneural—and overlap histologically with many other tumors, which may be diagnostically challenging to general surgical pathologists. Objective. —To review the clinical, morphologic, immunohistochemical, ultrastructural, cytogenetic, and molecular genetic aspects of perineurioma, as well as to discuss its clinicopathologic variants and differential diagnosis. Data Sources. —English-language literature published between 1966 and 2005 was reviewed. Conclusions. —The correct identification of perineuriomas is important to avoid unnecessary overtreatment. The histologic diagnosis should be confirmed through immunohistochemical studies (including epithelial membrane antigen, S100 protein, and more recently described antibodies such as claudin-1 and GLUT1) or electron microscopy. Cytogenetic and molecular genetic studies are still of limited value for the diagnosis of perineuriomas but may play a fundamental role in excluding important differential diagnoses and also in helping elucidate the biology of these poorly known neoplasms.